Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zeynep Eroglu

Showing results (51-60 of 116) with videos related to

Pageof 12
Sort By:
Pigment Cell & Melanoma Research|July 23, 2019
Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanomaZeynep Eroglu, Jennifer Eatrides, Syeda Mahrukh Hussnain Naqvi, et al.
Annals of Surgical Oncology|August 7, 2021
Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node DissectionKristy K Broman, Deepti Bettampadi, Jaileene Pérez-Morales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2BDiwakar Davar, Zeynep Eroglu, Mohammed Milhem, et al.
Journal of Neuro-Oncology|March 9, 2026
Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progressionVaseem M Khatri, Michael Aboujaoude, Lilit Karapetyan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2023
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanomaJulia Lai-Kwon, Sarah Jacques, Matteo Carlino, et al.
Cancer Immunology Research|April 12, 2017
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced MelanomaDaniel Y Wang, Zeynep Eroglu, Alpaslan Ozgun, et al.
Cancer Immunology Research|August 30, 2019
Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma PatientsDouglas B Johnson, Kevin B Taylor, Justine V Cohen, et al.
Cancer|March 4, 2023
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patientsZeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 6, 2024
Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods studyDanielle B Tometich, Carley Geiss, Melinda L Maconi, et al.
Pageof 12

Showing results (51-60 of 116) with videos related to

Sort By:
Pageof 12
Pigment Cell & Melanoma Research|July 23, 2019
Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanomaZeynep Eroglu, Jennifer Eatrides, Syeda Mahrukh Hussnain Naqvi, et al.
Annals of Surgical Oncology|August 7, 2021
Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node DissectionKristy K Broman, Deepti Bettampadi, Jaileene Pérez-Morales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2BDiwakar Davar, Zeynep Eroglu, Mohammed Milhem, et al.
Journal of Neuro-Oncology|March 9, 2026
Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progressionVaseem M Khatri, Michael Aboujaoude, Lilit Karapetyan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2023
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanomaJulia Lai-Kwon, Sarah Jacques, Matteo Carlino, et al.
Cancer Immunology Research|April 12, 2017
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced MelanomaDaniel Y Wang, Zeynep Eroglu, Alpaslan Ozgun, et al.
Cancer Immunology Research|August 30, 2019
Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma PatientsDouglas B Johnson, Kevin B Taylor, Justine V Cohen, et al.
Cancer|March 4, 2023
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patientsZeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 6, 2024
Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods studyDanielle B Tometich, Carley Geiss, Melinda L Maconi, et al.
Pageof 12